Thomas Glass, MD
Allergy & Immunology · Louisville, KYNPI 1992701833
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 356 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,823, 2.8 times the $656 reported in 2019. That places this record below the midpoint for allergy & immunology clinicians in KY, where the typical reported total is $7,092.
Across 356 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$936
- GSK$780
- Sanofi$650
- Kaleo, Inc.$447
- CSL Behring$436
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,68099%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 51 | $1,174 |
| AstraZeneca | 43 | $936 |
| GSK | 57 | $780 |
| Sanofi | 26 | $650 |
| Kaleo, Inc. | 25 | $447 |
| CSL Behring | 21 | $436 |
| Pfizer | 26 | $408 |
| Teva Pharmaceuticals USA, Inc. | 27 | $356 |
| Novartis | 11 | $237 |
| Optinose US, Inc. | 11 | $202 |
| Amgen | 11 | $199 |
| Genentech USA, Inc. | 10 | $188 |
| Grifols USA, LLC | 7 | $129 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $123 |
| Octapharma USA, Inc. | 4 | $105 |
| Blueprint Medicines Corporation | 5 | $101 |
| Azurity Pharmaceuticals, Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $40 |
| Merck | 2 | $35 |
| Boehringer Ingelheim | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Biocryst US Sales Co., LLC | 1 | $24 |
| Verona Pharma, Inc. | 1 | $23 |
| Circassia Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $14 |
| Alk-abello, Inc | 1 | $12 |
| Incyte Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,759 in reported general payments places this provider in the 45th percentile of 66 allergy & immunology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 15 | $107,023 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $94,245 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $30,206 |
| Epinephrine | 100 | $18,918 |
| Arnuity ElliptaFluticasone Furoate | 70 | $17,807 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $14,442 |
| DuleraMometasone/Formoterol | 34 | $11,820 |
| Spiriva RespimatTiotropium Bromide | 14 | $9,987 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $7,808 |
| Azelastine Hcl | 289 | $7,375 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $6,159 |
| Fluticasone Propionate | 379 | $4,778 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 119 | $3,074 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $2,943 |
| Montelukast Sodium | 321 | $2,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $436 | $107,02315 claims |
| Grifols USA, LLCGamunex-C | $129 | $94,24526 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $780 | $62,455144 claims |
| Hikma Pharmaceuticals USAEpinephrine | $18 | $18,918100 claims |
| MerckDulera | $35 | $11,82034 claims |
| Boehringer IngelheimSpiriva Respimat | $28 | $9,98714 claims |
| AstraZenecaSymbicort | $936 | $7,80817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 66 allergy & immunology providers in Kentucky.
Other allergy & immunology in Louisville
- James SublettLouisville$588K
- Stephen PollardLouisville$301K
- Douglas LotzLouisville$199K
- James SublettLouisville$194K
- Timothy FranxmanLouisville$162K
- Jeremy JonesLouisville$149K
- Mark CorbettLouisville$138K
- Kali GeraceLouisville$29K
- David PallaresLouisville$22K
- Joseph TurbyvilleLouisville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.